Aktis Oncology, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AKTS | ANL | KURA | RCUS | SNDX | PYXS | |
|---|---|---|---|---|---|---|
| Market cap | 845.42M | 618.86M | 676.99M | 2.43B | 940.80M | 198.30M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -7.1 | -32.7 | -3.2 | -6.2 | -14.4 | -1.5 |
| Price/book | 1.7 | 2.9 | 14.0 | 3.8 | -54.7 | 9.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −32.14% | +520.00% | −25.10% | −1.28% | −28.86% | −58.91% |
| Today | +1.74% | +0.31% | −22.98% | +2.12% | −26.87% | +1.22% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All AKTS news ›Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS)
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Aktis Oncology, Inc. today and set a price target of $34.00. According to TipRanks, Stranahan is a 4-star analyst with an average return of 8.8% and a 48.64%…
Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX) and Forte Biosciences (FBRX) with bullish sentiments. Aktis Oncology, Inc. (AKTS) In a…
Aktis Oncology (NASDAQ:AKTS) vs. Connect Biopharma (NASDAQ:CNTB) Head-To-Head Review
Posted by Danessa Lincoln on Oct 27th, 2026 Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Aktis Oncology (NASDAQ:AKTS – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast…
Aktis Oncology: Padcev Is Building The Market It Wants
Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves and two independent clinical programs. Read more on AKTS stock here. - Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves…
Aktis Oncology $AKTS Stock Purchased by Mirador Capital Partners LP
Posted by Kim Johansen on Oct 10th, 2026 Shares of AKTS stock opened at $18.15 on Friday. The stock has a market capitalization of $975.56 million and a PE ratio of -22.13. The business’s 50 day simple moving average is $22.96 and its 200…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com3
- themarketsdaily.com2
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.